Filana Therapeutics, Inc. (FLNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) has a cash flow conversion efficiency ratio of -0.061x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.85 Million) by net assets ($63.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Filana Therapeutics, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Filana Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Filana Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Filana Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Filana Therapeutics, Inc. ranked by their cash flow conversion efficiency. See how well can Filana Therapeutics, Inc. service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Culp, Inc. Common Stock
NYSE:CULP
|
-0.022x |
|
Verusaturk Girisim Sermayesi
IS:VERTU
|
0.003x |
|
Corentec Co Ltd
KQ:104540
|
0.100x |
|
US Energy Corp
NASDAQ:USEG
|
-0.006x |
|
Star Equity Holdings Inc
NASDAQ:STRR
|
-0.059x |
|
Minesto AB
ST:MINEST
|
-0.057x |
|
Adcorp
JSE:ADR
|
-0.111x |
|
Samwha Elec
KO:011230
|
-0.075x |
Annual Cash Flow Conversion Efficiency for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Filana Therapeutics, Inc. from 2022 to 2025. View latest Filana Therapeutics, Inc. stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $74.40 Million | $-32.25 Million | -0.433x | +45.98% |
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -- |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more